Cite
HARVARD Citation
Wymann, S. et al. (2022). Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo. Biochemical journal. 479 (9), pp. 1007-1030. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wymann, S. et al. (2022). Sialylation-dependent pharmacokinetics and differential complement pathway inhibition are hallmarks of CR1 activity in vivo. Biochemical journal. 479 (9), pp. 1007-1030. [Online].